公开(公告)号：WO0179144A3

公开(公告)日：2002-02-28

申请号：PCT/US0112039

申请日：2001-04-13

Applicant: COR THERAPEUTICS INC ,  COWAN KYRA J ,  LAW DEBBIE A ,  PHILLIPS DAVID R

Inventor： COWAN KYRA J ,  LAW DEBBIE A ,  PHILLIPS DAVID R

IPC: C07K14/705 ,  C12N9/12 ,  C07K14/00

CPC classification number: C07K14/70557 ,  C07K14/7055 ,  C07K14/70553

Abstract: The present invention describes a direct interaction between phosphorylated GPIIIa cytoplasmic domains with 1) src/ non- src family kinases and 2) phosphatases. The invention provides methods for identifying agents that block GPIIIa interactions with src/ non- scr family kinases and phosphatases, methods of using agents that block GPIIIa interactions with src/ non- src family kinases and PIP-1C phosphatases to modulate biological and pathological processes and agents that block GPIIIa mediated binding to src/ non- scr family kinases and PIP-1C phosphatases, thereby modulating related GPIIIa mediated signaling.

Abstract translation: 本发明描述了磷酸化GPIIIa细胞质结构域与1）src /非src家族激酶和2）磷酸酶之间的直接相互作用。 本发明提供用于鉴定阻断GPIIIa与非特异性家族激酶和磷酸酶的GPIIIa相互作用的试剂的方法，使用阻断GPIIIa与src / 非激活家族激酶和PIP-1C磷酸酶调节生物学和病理学过程，并阻断GPIIIa介导的结合于src / 家族激酶和PIP-1C磷酸酶，从而调节相关的GPIIIa介导的信号传导。

公开(公告)号：AU5534901A

公开(公告)日：2001-10-30

申请号：AU5534901

申请日：2001-04-13

Applicant: COR THERAPEUTICS INC

Inventor： COWAN KYRA J ,  LAW DEBBIE A ,  PHILLIPS DAVID R

IPC: C07K14/705

公开(公告)号：AU730864B2

公开(公告)日：2001-03-15

申请号：AU7458696

申请日：1996-10-18

Applicant: COR THERAPEUTICS INC

Inventor： PHILIPS DAVID ,  LAW DEBBIE A ,  ALAIMO LISA N

IPC: G01N33/53 ,  A61K38/00 ,  A61K45/00 ,  A61P7/02 ,  A61P9/00 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07K14/705 ,  C12N5/06 ,  C12N11/02 ,  C12N15/09 ,  A61K39/00 ,  A61K39/38 ,  G01N33/574 ,  A01N37/18

Abstract: The present invention discloses that phosphorylation of cytoplasmic tyrosine residues in the beta-subunit of integrins is needed for signal protein association. The invention provides methods of identifying signaling partners involved in integrin mediated signaling, methods of identifying agents which block integrin mediated signaling, methods of using agents which block integrin mediated signaling to modulate biological and pathological processes, and agents which block integrin mediated signaling.

公开(公告)号：NZ321304A

公开(公告)日：2000-08-25

申请号：NZ32130496

申请日：1996-10-18

Applicant: COR THERAPEUTICS INC

Inventor： PHILIPS DAVID ,  LAW DEBBIE A ,  ALAIMO LISA N

IPC: G01N33/53 ,  A61K38/00 ,  A61K45/00 ,  A61P7/02 ,  A61P9/00 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07K14/705 ,  C12N5/06 ,  C12N11/02 ,  C12N15/09 ,  C07K14/00 ,  A61K39/00 ,  G01N33/574 ,  A61K39/38 ,  A01N37/18

Abstract: Use of an agent particularly a phosphorylated peptide which blocks the binding of a cytoplasmic signaling partner to an integrin having a phosphorylated tyrosine in the cytoplasmic domain of the beta subunit or a fragment thereof comprising the phosphorylated cytoplasmic domain in the preparation of a medicament for blocking the interaction of an integrin with a cytoplasmic signaling partner in a patient, like thrombosis, inflammation and tumor metastasis. The signalling partner is selected from the src-family of tyrosine kinases and the non-src family of tyrosine kinases. Further disclosed is an in vitro method for identifying agents which block the interaction of an integrin with a cytoplasmic signalling partner by: a) incubating a peptide comprising the phosphorylated cytoplasmic domain of the beta subunit of the integrin with the signalling partner and with an agent and; b) determining whether the agent blocks the binding of the signalling partner to the peptide.

公开(公告)号：EP0801574A4

公开(公告)日：2002-09-04

申请号：EP96936741

申请日：1996-10-18

Applicant: COR THERAPEUTICS INC

Inventor： PHILLIPS DAVID ,  LAW DEBBIE A ,  ALAIMO LISA N

IPC: G01N33/53 ,  A61K38/00 ,  A61K45/00 ,  A61P7/02 ,  A61P9/00 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07K14/705 ,  C12N5/06 ,  C12N11/02 ,  C12N15/09 ,  A61K39/00 ,  A01N37/18 ,  A61K39/38 ,  G01N33/574

CPC classification number: C07K14/70546

Abstract: The present invention discloses that phosphorylation of cytoplasmic tyrosine residues in the β-subunit of integrins is needed for signal protein association. The invention provides methods of identifying signaling partners involved in integrin mediated signaling, methods of identifying agents which block integrin mediated signaling, methods of using agents which block intergrin mediated signaling to modulate biological and pathological processes, and agents which block integrin mediated signaling.